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I~  Creon ® for children is preferred by parents of CF patients to 
Creon ® 10000 MMS 
A. Munck 1 . On behalf of a group of French CF pediatricians. 1CF Cente~ H@ital 
Robert Debrd, Paris, France 
Introduction: Few data are available for pancreatic enzyme supplementation in young 
children. Creon ® for children (CFC) contains smaller granules (0.7 1.0 ram) as com- 
pared to Creon ® 10000 MMS (C). CFC is dosed using small spoon containing 5000 
lipase u per spoon, better suited to be administered to children and facilitating dosing 
of lipase u. < 10000 (capsule) as a single dose. 
Aim: Investigate parents' preference for CFC over C on a lipase/lipase basis and to 
evaluate fficacy of CFC on coefficient of fat absorption (CFA). 
Patients and methods: Design: open-label, CFC vs C (C is Creon ® 12000 U in France) 
2 periods cross-over, 14 days per period, fixed individual dose (based on previous 
dosage), treatment preference at end of 2nd cross-over period; CFA: dietary data (last 
96 h of each period), stool collection (last 72 h of each period). Inclusion criteria: age: 
6 36 months, proven CF, proven PEI ~>1 pancreatic function test. Statistics: Prescott's 
test for parent's preference; Wilcoxon test for within-subject differences (period II- 
period I) for stool parameters. 
Results: 40 patients enrolled, 19 randomized to CFC/C and 21 to C/CFC 
Demographics:  sex (M/F) 17/22; (mean±SD) age 19.2±9.5 months, weight 
10.1 kg±2.2, height 0.79m±0.09 
Parent's preference (ITT N 39) 
CFC/C C/CFC Total 
CFC N 8 12 20 
C N 3 6 9 
No preference N 7 3 10 
P 0.0662 
Secondary parameters (e.g. CFA, clinical symptomatology) showed very similar results 
for CFC and C. 2 unrelated SAEs were observed: 1on CFC, pseudomonal lung infection 
and 1 on C, bronchial obstruction. Safety was similarly good for both products. 
Conclusion: Parents' preference was higher for CFC to C with very similar effects on 
the treatment of maldigestion due to PEI in CF children (6 36 months). 
Acknowledgement:  the study was sponsored by Solvay Pharmaceuticals GmbH. 
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1~ Prognostic value of fecal elastase in children with Cystic Fibrosis 
C. Anne 1 , A. Hopp~ 1 , F. Troussier 1, E. Darviot 1, C. Pelatan 2, M.C. Chevalier 2, 
J.L. Gini~s 1. Centre de Ressources et de Compdtences pour la Mucoviscidose, 
1CHU, Angers; 2 CHR, Le Mans, France 
This study evaluated the impact of  maintaining normal exocrine pancreatic function 
on disease progression in children with cystic fibrosis, based on the fecal elastase 
test. 
This retrospective study of  62 patients followed at our university hospital included 
13 children with normal pancreatic function (fecal elastase >200 gg/g stool) com- 
pared with 26 children with pancreatic insufficiency (fecal elastase <100 gg/g stool) 
who were the closest in age: the two groups were strictly comparable for age 
(7±5 years) and sex. 
Among the patients with normal pancreatic function, 9 were heterozygous for 
the AF508 mutation and 4 did not carry it. Among the patients with pancreatic 
insufficiency, 16 were homozygous for the AF508 mutation, 9 were heterozygous 
and 1 did not carry it (p <0.001). Compared with the patients with pancreatic 
insufficiency, the patients with normal pancreatic function had significantly fewer 
bowel movements (1.4±0.7 vs. 2.1±0.8 per day, p <0.01), a less elevated sweat 
chloride concentration (86±22 vs. 102±16 mmol/1, p < 0.05), a better Shwachman 
score (93±4 vs. 85± 11, p < 0.01), a higher BMI-for-age z score (97± 12 vs. 89±8%, 
p < 0.05), more elevated serum iron (17±5 vs. 12±6 gmol/1, p < 0.01) and vitamin A 
(1.9±0.4 vs. 1.6±0.4 gmol/1, p < 0.05), and less reduced FEV1 for age (98±19 vs. 
77±26%, p < 0.01). 
Normal pancreatic function, defined as fecal elastase >200 gg/g stool, was associ- 
ated with better intestinal, nutritional and respiratory status in children with cystic 
fibrosis. 
I •  Pancreatic enzymes consumption by CF patients in France 
F. Dyard 1 , S. Ravilly 2, G. Bellis 3. 1Solvay Pharma, Suresnes, 2 VLM, 3INED, Paris, France 
Introduction: French CF patients are mainly followed in CF centres. In 2003, 87.1% of CF 
patients were receiving astroprotected pancreatic enzymes (GPE). No GPE consumption data were 
available, especially for overdosing (French recotrmlendations: children ~<10,000IU/kg/day, adults 
~<250,000 IU/day). 
Patients and methods: Inclusim~/non-inclusion criteria: all patients included in 'Observatoire Na- 
tim/al de la Mucoviscidose' (ONM) cohort (4048 patients; estimated to cover 80% of the total 
CF population). Statistics: GPE cotlsumers: 87% (from ONM); expected overdosage: 15% (from 
previous clinical study); 95%CI: 3%; 600 patients were needed to get 550 completed CRE Sample 
randomly extracted from ONM file managed by INED. Data collection: October November 2005, 
retrospectively, byextert/al clinical research assistants. 
Results: Demographics gender (M/F): 51.3%/48.7%; (meam+SD) age at collection date: 
17.5±9.9 yrs; weight: 42.2±16.5 kg, height: 150.1±24.7 cm, BMI: 18.0±2.9 kg/m 2. Disease age 
(months) at CF diagnosis: 28.7±56.1, median 4.5, at PEI diagnosis: 17.1±34.1, median 5.0, 
mutation 1: delta-F508: 86.4%, mutation 2: delta-F508: 50.9%. 
Table 1: GPE consumptiolgage. 
Dosage (IU/kg) Age (yt~) in 2005 by classes Total 
[0;5[ [5;10[ [10;15[ [15;18[ >18 
N 41 103 81 57 269 551 
Mean 7610.1 7199.7 5755.4 5023.9 4140.4 5299.3 
SD 4221.8 4183.1 3239.8 2452.7 2464.0 3377.7 
Minimum 1224 240 825 883 304 240 
Maximum 19231 32450 15432 11574 14286 32450 
Table 2: GPE consumption n CF patients. 
Children Adults 
Frequency % Frequency % 
Valid Daily overdosage 30 12.5 107 31.9 
Non daily overdosage 195 81.3 228 68.1 
Missing 15 6.3 
Total 240 100.0 335 100.0 
Conclusion: Despite frequent GPE overdosage (as defined) /,1 French CF patients (children and 
adults), cases of fibrosing colonopathy have never been reported/,1 France. 
1• Supervising the transition to an alternative enzyme preparation 
from Pancrease ® in one regional adult CF centre 
S. Pandya, A. Sobanska, J. Crawley, M.J. Ledson, M.J. Walshaw. Regional Adult 
CF Unit, The Cardiothoracic Centre, Liverpool, UK 
Introduct ion:  Replacement pancreatic enzymes are essential for most CF patients 
but the dose and type must be tailored to individual needs. In 2005 a manufacturing 
problem with Pancrease ® resulted in supply diffÉculties, prompting us to switch 
some patients to other products. We have monitored the results of this attempted 
change in enzyme therapy. 
Methods:  28 patients (average age 27 years [range 19 44], mean BMI 23 [18 30]); 
18 male), were taking Pancrease. Under supervision of  the CF dieticians, all 
attempted to change to Creon ® 10,000. 
Results: 3 (11%) could not tolerate Creon and were unwilling to try another 
preparation: they continued to receive Pancrease on a named patient basis from the 
manufacturer. 17 (61%) changed to Creon without problems, exchanging a daily 
average of 45 Pancrease capsules [7 98] (3447 ius lipase/kg/day [469 8135]) for a 
daily average of 29 Creon capsules [3 65] (4250 ius lipase/kg/day [536 10062]). 
A further patient taking 28 Pancrease capsules daily (2745 ius lipase/kg) could not 
tolerate Creon but changed to 10 Nutrizym ® capsules per day (2040 ius lipase/kg). 
O f  those that changed to Creon, 4 (20%) complained of abdominal pain which 
resolved after dose adjustment. None complained of steatorrhoea. 
Only 1 (5%) is unhappy with the change, since they are taking more capsules than 
before, but 2 (25%) are still taking >10,000 ius lipase/kg/day. 
Conclus ion:  Patients can successfully change to alternative nzyme preparations 
with dietetic support. Although patients on Creon are taking fewer capsules 
they are taking more lipase/kg. Those that are exceeding the recommended ose 
are monitored for abdominal problems, using food and enzyme diaries closely 
supervised by the CF dieticians. 
